EPISODE · Nov 26, 2024 · 16 MIN
Leprosy 101: Managing Reactions and Complications | ASkinMD E11
from ASkinMD - Clinical Excellence in Skin, Hair, and Regenerative Medicine · host Dr. Rakshitha Jayaprakash
In this episode of ASkinMD, Dr. Rakshitha Jayaprakash focuses on managing reactions and complications associated with leprosy, referencing Chapters 5 and 8 of Jopling's Handbook and Chapters 32, 33, and 37 of the IAL textbook. Listeners will gain a comprehensive understanding of Type 1 (reversal) and Type 2 (erythema nodosum leprosum) reactions, including their clinical features and underlying mechanisms. The episode will explore effective management strategies, highlighting the use of corticosteroids for Type 1 reactions and thalidomide along with NSAIDs for Type 2 reactions. Additionally, Dr. Jayaprakash emphasizes the importance of rehabilitation and follow-up care in preventing disability and improving the quality of life for individuals affected by leprosy. This informative session is essential for healthcare professionals seeking to enhance their understanding of leprosy management. Keywords: leprosy reactions, Type 1 reactions, Type 2 reactions, reversal reactions, erythema nodosum leprosum, leprosy management, ASkinMD, dermatology podcast. #Leprosy #Reactions #DermatologyEducation #MedicalPodcast #ASkinMDSupport the show
What this episode covers
In this episode of ASkinMD, Dr. Rakshitha Jayaprakash focuses on managing reactions and complications associated with leprosy, referencing Chapters 5 and 8 of Jopling's Handbook and Chapters 32, 33, and 37 of the IAL textbook. Listeners will gain a comprehensive understanding of Type 1 (reversal) and Type 2 (erythema nodosum leprosum) reactions, including their clinical features and underlying mechanisms. The episode will explore effective management strategies, highlighting the use of ...
NOW PLAYING
Leprosy 101: Managing Reactions and Complications | ASkinMD E11
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m